A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers. - Fujita R; Blot V; Wong E; Stewart C; Lieuw V; Richardson R; Banah A; Villicana J; Timmer A; Coronella J; Newman R; Gymnopoulos M (Cancer biology & therapy, 2020)